SCHEMBL17015376

SCHEMBL17015376

O=C(c1ccccc1)c1cccc(-n2c3ccccc3c3ccc4ccn(-c5ccccc5)c4c32)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.39
ATM Q13315 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
FOLH1 Q04609 1/20 0.38
PLA2G10 O15496 1/20 0.37
CNR2 P34972 1/20 0.37
ALOX15 P16050 2/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
ALDH1A1 P00352 4/20 0.35
GLA P06280 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HPGD P15428 2/20 0.35
PBRM1 Q86U86 1/20 0.35
HSD17B10 Q99714 2/20 0.35
USP2 O75604 1/20 0.35
MYC P01106 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17016250 0.95 ATM (0.39) L3MBTL1ATMTDP1FOLH1PLA2G10
SCHEMBL17015379 0.93 CLK1 (0.40) FOLH1PLA2G10CNR2ALOX15MEN1
SCHEMBL17015374 0.92 L3MBTL1 (0.40) L3MBTL1ATMTDP1CNR2ALOX15
SCHEMBL17016249 0.92 L3MBTL1 (0.40) L3MBTL1ATMTDP1CNR2ALOX15
SCHEMBL17015378 0.89 ACHE (0.40) L3MBTL1ATMCNR2ALOX15KDM4E
SCHEMBL17016253 0.89 ACHE (0.40) L3MBTL1ATMCNR2ALOX15KDM4E
SCHEMBL17016254 0.89 CLK1 (0.40) L3MBTL1ATMCNR2ALOX15KDM4E
SCHEMBL17016322 0.88 ALDH1A1 (0.40) L3MBTL1ATMTDP1CNR2KDM4E
SCHEMBL15632219 0.88 KDM4E (0.43) L3MBTL1ATMFOLH1KDM4EMEN1
SCHEMBL17015389 0.86 KDM4E (0.46) L3MBTL1ATMFOLH1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 L3MBTL1 533/4885ATM 3623/4885TDP1 2483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.